Response to Comment on: “Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasiarelated changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin”